Acknowledgement
This project was conducted under the auspices of Korean Brain Tumor Society (KBTS).
References
- Aguilera D, Castellino RC, Janss A, Schniederjan M, McNall R, MacDonald T, et al. : Clinical responses of patients with diffuse leptomeningeal glioneuronal tumors to chemotherapy. Childs Nerv Syst 34 : 329-334, 2018 https://doi.org/10.1007/s00381-017-3584-x
- Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. : Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374 : 1344-1355, 2016 https://doi.org/10.1056/NEJMoa1500925
- Bunevicius A, Sheehan JP : Radiosurgery for glioblastoma. Neurosurg Clin N Am 32 : 117-128, 2021 https://doi.org/10.1016/j.nec.2020.08.007
- Dono A, Ballester LY, Primdahl D, Esquenazi Y, Bhatia A : IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions. Curr Oncol Rep 23 : 20, 2021
- Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, et al. : A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis†. Neurooncol Pract 3 : 272-280, 2016
- Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. : Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, openlabel, phase 3 trial. Lancet 393 : 678-688, 2019 https://doi.org/10.1016/S0140-6736(18)31791-4
- Hingorani M, Colley WP, Dixit S, Beavis AM : Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? Br J Radiol 85 : e770-e781, 2012 https://doi.org/10.1259/bjr/83827377
- Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, et al. : CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol 23 : 457-467, 2021 https://doi.org/10.1093/neuonc/noaa168
- Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, et al. : Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 18 : 1442-1450, 2016 https://doi.org/10.1093/neuonc/now038
- Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. : BRAF inhibition in BRAFV600-mutant gliomas: results from the VEBASKET study. J Clin Oncol 36 : 3477-3484, 2018 https://doi.org/10.1200/JCO.2018.78.9990
- Karschnia P, Young JS, Dono A, Hani L, Sciortino T, Bruno F, et al. : Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol, 2022 [Epub ahead of print]
- Kim YZ, Kim CY, Lim DH : The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat 10 : 83-93, 2022 https://doi.org/10.14791/btrt.2022.0001
- Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, et al. : The Korean Society for Neuro-Oncology (KSNO) guideline for glioblastomas: version 2018.01. Brain Tumor Res Treat 7 : 1-9, 2019 https://doi.org/10.14791/btrt.2019.7.e25
- Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, et al. : The Korean Society for Neuro-Oncology (KSNO) guideline for WHO grade III cerebral gliomas in adults: version 2019.01. Brain Tumor Res Treat 7 : 63-73, 2019 https://doi.org/10.14791/btrt.2019.7.e42
- Kim YZ, Kim CY, Wee CW, Roh TH, Hong JB, Oh HJ, et al. : The Korean Society for Neuro-Oncology (KSNO) guideline for WHO grade II cerebral gliomas in adults: version 2019.01. Brain Tumor Res Treat 7 : 74-84, 2019 https://doi.org/10.14791/btrt.2019.7.e43
- Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, et al. : Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol 40 : 2539-2545, 2022
- Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. : Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79 : 1487-1495, 2011 https://doi.org/10.1016/j.ijrobp.2009.12.061
- Lombardi G, De Salvo GL, Brandes AA, Eoli M, Ruda R, Faedi M, et al. : Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20 : 110-119, 2019 https://doi.org/10.1016/S1470-2045(18)30675-2
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. : The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23 : 1231-1251, 2021 https://doi.org/10.1093/neuonc/noab106
- Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, et al. : Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 25 : 4-25, 2023
- Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. : Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 40 : 403-426, 2022
- National Comprehensive Cancer Network : Central Nervous System Cancers (version 2.2022). Available at : https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425
- Selt F, van Tilburg CM, Bison B, Sievers P, Harting I, Ecker J, et al. : Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol 149 : 499-510, 2020 https://doi.org/10.1007/s11060-020-03640-3
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 https://doi.org/10.1056/NEJMoa043330
- Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. : Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15 : 943-953, 2014
- van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. : Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390 : 1645-1653, 2017 https://doi.org/10.1016/S0140-6736(17)31442-3
- van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. : Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31 : 344-350, 2013
- van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, et al. : Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22 : 813-823, 2021 https://doi.org/10.1016/S1470-2045(21)00090-5
- Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. : EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18 : 170-186, 2021 https://doi.org/10.1038/s41571-020-00447-z
- Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. : Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23 : 53-64, 2022 https://doi.org/10.1016/S1470-2045(21)00578-7
- Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. : Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22 : 1073-1113, 2020 https://doi.org/10.1093/neuonc/noaa106
- WHO Classification of Tumours Editorial Board : Central Nervous System Tumours. Lyon : International Agency for Research on Cancer, 2021
- Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. : Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377 : 1954-1963, 2017 https://doi.org/10.1056/NEJMoa1707358
- Yoon HI, Wee CW, Kim YZ, Seo Y, Im JH, Dho YS, et al. : The Korean Society for Neuro-Oncology (KSNO) guideline for adult diffuse midline glioma: version 2021.1. Brain Tumor Res Treat 9 : 1-8, 2021 https://doi.org/10.14791/btrt.2021.9.e8
- Zhuang H, Yuan X, Zheng Y, Li X, Chang JY, Wang J, et al. : A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep 6 : 24364, 2016